Chapter 3 - THE MONEY THAT REQUIRED LEO TO DIE
Leo’s illness was not the beginning of the conspiracy.
Money was.
My grandfather, Elias Voss, founded Voss Biomedical Manufacturing after the Korean War.
The company produced surgical instruments, laboratory equipment, and eventually advanced transfusion systems.
By the time he died, the company was worth hundreds of millions.
He left voting shares divided among family branches.
My mother received twenty-one percent.
Philip and I each received smaller direct interests.
A protected trust held thirty-four percent for the first grandchild of my generation.
That child was Leo.
The trust terms were old, rigid, and badly designed.
If Leo reached eighteen, the shares would vest under independent management.
If he died before eighteen, the shares reverted to the surviving family line controlled by Beatrice and Philip.
I had challenged the clause after Nora died.
My attorney said changing it required agreement from every residual beneficiary.
Beatrice refused.
“It is your grandfather’s intention,” she said.
“It makes my sick son’s death financially valuable to his relatives.”
“That is an ugly way to describe inheritance.”
“It is an accurate way.”
Philip accused me of treating him like a criminal.
At the time, I apologized.
Six months later, Voss Biomedical faced a serious crisis.
Philip had become chief executive after I sold Sentinel Ward and left the family company.
He expanded too quickly.
Three manufacturing projects failed.
A regulatory investigation delayed a major device approval.
Private lenders demanded repayment.
The company needed more than seventy million dollars within a year.
Leo’s trust shares could not be borrowed against.
The trustees would not permit a sale.
If the shares reverted to Beatrice and Philip, they could pledge or sell them immediately.
Celeste managed Philip’s personal investments.
She knew every debt.
My mother knew the family company might collapse under her son.
Neither approached me honestly.
Perhaps they believed I would refuse.
They were right.
I would have protected employees and legitimate operations.
I would not have transferred Leo’s inheritance to cover Philip’s concealed losses.
The syringe created a direct path.
If Leo died from complications of his disorder, Beatrice and Philip gained the shares.
If suspicious medicine was found missing, Mara carried the blame.
If I questioned the event, grief could be described as paranoia.
They had already prepared that narrative.
Celeste’s tablet contained messages with Dr. Arthur Vale.
He was not related to us despite sharing the surname.
He had treated Beatrice for years and advised Voss Biomedical on clinical matters.
CELESTE: HIS NUMBERS ARE WORSE. HOW MUCH WOULD LOOK NATURAL?
DR. VALE: NOTHING IS PREDICTABLE WITH THIS CONDITION.
CELESTE: I ASKED WHAT WOULD NOT TRIGGER AN AUTOPSY.
DR. VALE: A SEVERE CLOTTING EVENT COULD OCCUR SPONTANEOUSLY.
Another message:
BEATRICE: THE CAREGIVER HAS A THEFT HISTORY.
CELESTE: SHE’S PERFECT.
BEATRICE: ADRIAN MUST SEE THE VIAL IN HER HAND.
CELESTE: THE CAMERA WILL.
The messages were discovered after police obtained warrants.
But even before that, the financial motive appeared inside a draft board presentation found on Philip’s laptop.
PROJECTED CAPITAL RESTRUCTURING — CONTINGENT FAMILY SHARE REVERSION.
The presentation assumed the trust shares would become available within thirty days.
Leo was alive when Philip created it.
The file included no explanation for why the shares would revert.
A second spreadsheet listed:
Medical transition date: Pending.
Trust control date: +14 days.
Debt facility closing: +21 days.
They had built a refinancing schedule around my son’s death.
Philip claimed later that “medical transition” referred to a possible guardianship change.
The trust did not permit control through guardianship.
Only death triggered reversion.
My mother’s role was more personal.
Beatrice believed the family company represented her father’s legacy.
She considered my independent wealth an insult because I had built Sentinel Ward outside Voss Biomedical.
Philip remained loyal to her authority.
I did not.
“Your son is one child,” she told me during an argument months before the nursery discovery. “The company supports three thousand families.”
“Leo is not a negotiable sacrifice.”
“I did not say that.”
“You described his inheritance as if it belonged to the company.”
“It should.”
“It belongs to him.”
“He is five.”
“Children can own property even when adults dislike it.”
Her expression turned cold.
“Nora taught you to speak to me like an enemy.”
“No. Nora taught me to notice when love demands surrender.”
That was the last private argument I had with my mother before I installed the secondary system.
After the syringe was discovered, Dr. Park ordered a full toxicology review of Leo’s recent blood samples.
The results showed traces of a clot-promoting medication not included in his treatment plan.
The amount was small.
Repeated.
Enough to destabilize him.
The altered vial contained a higher concentration.
The syringe contained the same substance.
Someone had been manufacturing medical deterioration while allowing the underlying disorder to take the blame.
May you like
Leo was not simply becoming sicker.
He was being made harder to save.
